CFTR and cystic fibrosis: In an early clinical trial of patients with either one or two copies of F508del CFTR, CF patients treated with this triple drug combination displayed a 10% improvement in FEV1 on average, along with a sharp, concomitant drop in sweat chloride and a significantly reduced frequency of pulmonary exacerbations.